Our biomedical venture philanthropy model adapts the operating principles of venture capital investing to the Alzheimer Drug Discovery Foundation’s philanthropic mission to advance biomedical research in Alzheimer’s disease. We seek a return on investment for our grants based on the achievement of scientific and/or business milestones. When these milestones are met, funds come back to the Foundation to increase our ability to fund more research.
Government and traditional foundations tend to fund basic research while pharmaceutical companies and venture capitalists favor supporting late-state research and late-stage clinical trials. The ADDF biomedical venture philanthropy model fills the funding gap by supporting the critical translational research of academic and industry scientists.